Study guide

2.2 Neuropathy & Monofilament Testing in Diabetic Patients

NAWCCB WCC Wound Care Certified Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

About the NAWCCB WCC Exam How to Use This Study Guide

2 Assessment: Skin & Tissue Foundations

1.1 Skin Anatomy, Physiology, and Barrier Function 1.2 Phases of Wound Healing & Cellular Events 1.3 Acute vs. Chronic Wounds & Etiology Classification 1.4 TIME and MEASURE Assessment Frameworks 1.5 Wound Bed Tissue Types & Periwound Assessment 1.6 Pain Assessment: Scales, Wound Pain Types, and Procedural Analgesia 1.7 Psychosocial History, Cognitive Status, and Functional Assessment 1.8 Skin Integrity Across the Lifespan: Neonatal, Pediatric, Adult, and Geriatric

3 Assessment: Diagnostic Tools & Risk Assessment

2.1 Vascular Assessment: ABI, TcPO2, and Arterial/Venous Doppler 2.2 Neuropathy & Monofilament Testing in Diabetic Patients 2.3 Pressure Injury Risk Assessment: Braden Scale Subscales & Scoring 2.4 NPIAP Pressure Injury Staging (Stages 1-4, Unstageable, DTPI) 2.5 Exudate Characterization, Biofilm (NERDS/STONEES), & Wound Culture 2.6 Laboratory Interpretation in Wound Care: Albumin, Prealbumin, ESR, A1C, CBC, and CMP 2.7 Risk Assessment Instruments Beyond Braden: Norton, Braden Q, Braden QD, Wagner, and University of Texas

4 Treatment: Dressing Selection & Debridement Modalities

3.1 Principles of Dressing Selection by Exudate & Moisture Balance 3.2 High-Absorbency Dressings: Alginates, Hydrofibers, and Foams 3.3 Barrier & Hydrating Dressings: Hydrocolloids, Transparent Films, and Hydrogels 3.4 Antimicrobial & Biofilm Dressings: Silver, Cadexomer Iodine, and Honey 3.5 Debridement Modalities: Sharp, Enzymatic, Autolytic, Mechanical, & Biosurgical

5 Treatment: Advanced Therapies & Specialized Management

4.1 Negative Pressure Wound Therapy (NPWT) Indications, Settings, & Precautions 4.2 Compression Therapy Protocols & ABI Safety Cutoffs 4.3 DFU Off-loading Hierarchy: TCC, RCW, and Therapeutic Footwear 4.4 Support Surfaces, Microclimate Control, & Repositioning Protocols 4.5 Advanced Biologics, Cellular/Tissue Products (CTPs), & HBOT

6 Reevaluation & Wound Healing Trajectory

5.1 Healing Trajectory Benchmarks & Percent Area Reduction (PAR) 5.2 Serial Wound Measurement, Depth Profiling, & Digital Photography 5.3 Treatment Plan Reassessment & Non-Healing Wound Escalation Triggers 5.4 Biofilm Progression & Systemic Infection Re-evaluation 5.5 Palliative Wound Management: Odor, Exudate, and Pain Control 5.6 Validated Healing Instruments: The PUSH Tool, BWAT, and Evaluating Adherence

7 Risk Reduction & Prevention Strategies

6.1 Pressure Injury Prevention: Bundles, Turning Schedules, & Heel Floating 6.2 Moisture-Associated Skin Damage (MASD) & Incontinence-Associated Dermatitis (IAD) 6.3 Infection Control, Contact Precautions, & Environmental Hygiene 6.4 Prevention of Skin Tears & Medical Adhesive-Related Skin Injuries (MARSI) 6.5 Diabetic & Venous Ulcer Recurrence Prevention Protocols 6.6 At-Risk Populations: Spinal Cord Injury, Stroke, Critical Care, and Cognitive Impairment

8 Patient & Caregiver Education

7.1 Patient & Caregiver Wound Care Teaching & Self-Management 7.2 Diabetic Foot Self-Inspection & Footwear Education 7.3 Nutritional Assessment & Dietary Interventions for Wound Healing 7.4 Off-loading Compliance & Patient Mobility Education 7.5 Recognizing Complications, Infection Signs, & When to Seek Care 7.6 Educating the Interprofessional Team & Developing Educational Media

9 Administration & Program Management

8.1 Wound Care Documentation Standards & Clinical Records 8.2 Admission Wound Screening & Present on Admission (POA) Documentation 8.3 Interdisciplinary Team Roles & Clinical Care Coordination 8.4 Quality Improvement Metrics & HAPI Tracking Programs 8.5 Wound Care Formulary Management & Resource Utilization

10 Legal, Ethical, & Scope of Practice

9.1 Informed Consent, Treatment Refusal, & Autonomy in Wound Care 9.2 HIPAA Compliance & Clinical Photography Privacy Standards 9.3 Scope of Practice Across WCC-Eligible Professions (RN, LPN, PT, OT, DPM, MD/DO, PA) 9.4 HAPI Malpractice Liability & Documentation Defense 9.5 Ethical Considerations in Non-Healing Wounds & End-of-Life Skin Care 9.6 Regulatory Compliance, Coding Standards, & Audit Protection

2.2 Neuropathy & Monofilament Testing in Diabetic Patients

Key Takeaways Explain This Topic AI

The 10-gram Semmes-Weinstein monofilament (size 5.07) evaluates Loss of Protective Sensation (LOPS); failure to sense the monofilament at 2 or more sites out of 10 indicates LOPS.

The standard 10-point test location map includes the plantar 1st, 3rd, and 5th distal hallux/digits, 1st, 3rd, and 5th metatarsal heads, midfoot medial and lateral borders, heel, and the dorsal web space.

Monofilament application technique requires holding the filament perpendicular to the skin and pushing until it buckles for 1.5 seconds, while completely avoiding calluses, open ulcers, scars, or necrotic tissue.

Vibratory sensation testing with a 128 Hz tuning fork and Vibration Perception Threshold (VPT) testing using a Biothesiometer (>25 Volts) detect early large-fiber sensory neuropathy.

Diabetic peripheral neuropathy involves a clinical triad: sensory loss (unperceived microtrauma), motor neuropathy (muscle atrophy and toe deformities), and autonomic neuropathy (anhidrosis and skin fissuring).

Last updated: August 2026

Neuropathy & Monofilament Testing in Diabetic Patients

Diabetic Peripheral Neuropathy (DPN) affects up to 50% of individuals with long-standing diabetes mellitus and is the leading predisposing factor for diabetic foot ulceration (DFU) and non-traumatic lower extremity amputation. Neuropathy deprives the patient of early warning signals, permitting repetitive mechanical shear and pressure to cause tissue breakdown unnoticed. Clinical assessment requires systematically evaluating the triad of diabetic nerve damage and quantifying Loss of Protective Sensation (LOPS) .

Pathophysiology: The Neuropathic Triad

Chronic hyperglycemia induces nerve ischemia, oxidative stress, and accumulation of advanced glycation end-products (AGEs), leading to progressive damage across three distinct nerve fiber pathways:

Sensory Neuropathy (Small & Large Fibers):

Distal symmetric "glove-and-stocking" sensory loss.

Deprives the individual of pain and temperature awareness.

Allows repetitive minor trauma (e.g., a small stone in a shoe or tight footwear) to cause painless tissue ulceration.

Motor Neuropathy (Motor Nerve Fibers):

Causes atrophy of intrinsic foot musculature (lumbricals and interossei).

Results in muscle imbalance, flexor tendon pull dominance, and structural deformities such as claw toes , hammer toes , and prominent metatarsal heads .

Alters gait kinematics and significantly shifts plantar peak pressure points directly onto unpadded bony prominences.

Autonomic Neuropathy (Sympathetic Fibers):

Causes loss of sweat gland function ( anhidrosis ) and reduced sebaceous secretion.

Results in dry, hyperkeratotic, fissured skin prone to cracking and bacterial entry.

Disrupts microvascular tone, leading to arteriovenous shunting, warm dry skin, and bone demineralization associated with Charcot neuroarthropathy .

Semmes-Weinstein Monofilament Examination (SWME)

The 10-gram Semmes-Weinstein Monofilament (calibrated size 5.07 ) is the gold-standard bedside screening instrument for identifying Loss of Protective Sensation (LOPS). Monofilament Testing Technique:

  • Clinician Hand Monofilament (5.07 / 10g)
  • [====]---------------\
  • \ (Perpendicular application)
  • \ Buckles for 1.5 seconds
  • V
  • ================= Skin Surface
  • Clinical Testing Protocol

Patient Orientation: Place the patient in a comfortable supine or seated position. Demonstrate the test by applying the monofilament to the patient's forearm or hand so they understand the sensation.

Testing Conditions: Instruct the patient to close their eyes and say "yes" whenever they feel the pressure touching their foot.

Application Technique:

Hold the monofilament perpendicular (90°) to the skin surface.

Apply steady pressure until the monofilament bends or buckles into a C-shape.

Maintain the buckled pressure against the skin for approximately 1.5 seconds , then release.

Do not slide the monofilament across the skin or apply it rapidly in a repetitive tapping movement.

Diagnostic Criteria for LOPS:

Testing is performed across 10 standard anatomical sites per foot.

Failure to feel the monofilament at 2 or more sites out of 10 establishes a diagnosis of Loss of Protective Sensation (LOPS) .

The 10-Point Monofilament Site Map & Exclusions

The standard clinical examination checks 9 plantar locations and 1 dorsal location per foot:

  • Plantar distal phalanx of the 1st digit (hallux)
  • Plantar distal phalanx of the 3rd digit
  • Plantar distal phalanx of the 5th digit
  • Plantar surface of the 1st metatarsal head
  • Plantar surface of the 3rd metatarsal head
  • Plantar surface of the 5th metatarsal head
  • Plantar midfoot medial border
  • Plantar midfoot lateral border
  • Plantar surface of the heel
  • Dorsal web space between the 1st and 2nd toes

Critical Testing Rule: NEVER apply the monofilament directly over hyperkeratotic calluses, open wounds, surgical scars, or necrotic tissue. Thick callus tissue absorbs the 10g force and produces false-negative results. Test immediately adjacent to calluses or ulcers on intact, normal-thickness skin.

Advanced Neurological Assessment Modalities

While the 10g monofilament evaluates coarse tactile sensation, comprehensive neurological workups incorporate additional modalities to detect early nerve damage:

128 Hz Tuning Fork (Vibratory Perception): Applied to the bony prominence of the distal hallux interphalangeal joint. The clinician notes whether the patient perceives vibration and performs a timed disappearance test compared to their own hand.

Biothesiometer / Vibration Perception Threshold (VPT): A quantitative electronic device delivering variable amplitude 100 Hz vibrations to the hallux or metatarsal heads:

VPT < 15 Volts: Normal vibratory sensitivity.

VPT 15 – 25 Volts: Moderate vibratory loss.

VPT > 25 Volts: Severe large-fiber sensory neuropathy; associated with a >7-fold increase in foot ulceration risk.

Pinprick & Temperature Testing: Evaluates small-fiber spinothalamic nerve tract integrity using cold/warm probes or sterile safety pins.

Achilles Tendon Reflex (Ankle Jerk): Evaluates deep tendon reflex integrity (S1 root), which is typically lost early in DPN.

Risk Category Clinical Characteristics Ulcer Risk Level Recommended Examination Frequency Required Clinical Interventions

Category 0 No LOPS, No PAD Very Low Risk Annually Basic diabetic foot care education; proper footwear

Category 1 LOPS Present (No PAD, No Deformity) Low Risk Every 3 to 6 Months Patient self-inspection education; custom soft insoles

Category 2 LOPS + PAD, OR LOPS + Foot Deformity Moderate Risk Every 1 to 3 Months Prescription extra-depth footwear; custom orthotics; podiatry

Category 3 LOPS + History of Ulcer or Amputation High Risk Every 1 to 2 Months Specialized offloading; vascular team care; daily mirror checks

Loading diagram... 10-Point Plantar Monofilament Examination Protocol